

VI. BIBLIOGRAPHY

1. Aaby P, Bukh J, Lisse IM, Smith AJ. Overcrowding and intensive exposure as determinants of measles mortality. *Am. J. Epidemiol.* 1984; 120(1): 49-63.
2. Aaby P, Bukh J, Leerhoy J, Lisse IM, Mordhorst CH, Pedersen IR. Vaccinated children get milder measles infection : A community study from Guinea Bissau. *J. Infect. Dis.* 1986; 154(5): 858-63.
3. Ademuwagun ZA. Traditional beliefs about measles and its treatment among the Bambara of Mali. *African Therapeutic System : Wattham Masachussets Cross Road Press.* 1979; 19-21.
4. Agarwal D, Dutta A, Arora RR, Nair MRV. Natural history of measles in rural and urban community of Varanasi. *J. Comm. Dis.* 1976; 8(4): 289-98.
5. Agrawal SK. Study of passive measles immunity in the first year of life and seroconversion response following vaccination at 6-12 months of age. Dissertation submitted to Delhi University, New Delhi for M.D (Paed.); 1988.
6. Ajjan N, Soulebot JP, Stellmann C et al. Combination of attenuated measles vaccine (Schwarz) with meningococcus A and A + C vaccine. *Dev. Biol. Stand.* 1978; 41: 209-16.
7. Albrecht P, Ennis FA, Saltzman EJ, Krugman S. Persistence of maternal antibody in infants beyond 12 months : mechanism of measles vaccine failures. *J. Pediatr.* 1977; 91(5): 715-8.
8. Albrecht P, Lorenz D, Klutch MJ, Vickers JH, Ennis FA. Fatal measles infection in marmosets : pathogenesis and prophylaxis. *Infect. Immun.* 1980; 27: 969-78.
9. Alexander ER, Bansmer CAM, Harris ES et al. Measles vaccination in infants. *Am. J. Dis. Child.* 1964; 108: 470-8.
10. Ambrus JL. Global health care (Editorial). *J. Med. Clin. Exp. Theor.* 1980; 11(5-6): 321-8.

11. Anderson JF, Goldberger J. Experimental measles in the monkey : a preliminary report. Public Health Rep. 1911; 26: 847. As cited in 89.
12. Anderson RM, May RM. Vaccination and herd immunity to infectious diseases. Nature. 1985; 318: 323-9.
13. Assad F. Measles: Summary of worldwide impact. Rev. Infect. Dis. 1983; 5(3): 452-9.
14. Awdrey PN, Cobb B, Adams PCG. Blindness in the Luapula valley. Central Afr. J. Med. 1967; 13: 197.
15. Banker DD. Modern practice in immunisation. Popular Prakashan, Bombay. 1980; 239-55.
16. Baratta RO, Ginter MC, Price MA et al. Measles (rubeola) in previously immunised children. Pediatrics. 1970; 46: 397-402.
17. Barbor PRH, Grant DB. Encephalitis after measles vaccination. Lancet. 1962; 2: 55-6.
18. Basu RN, Bhatia R, Ichhpujani RL. Manual on laboratory procedures of common epidemic-prone diseases. Measles. NICD, Delhi. 1984.
19. Basu RN. Measles vaccine feasibility, efficacy and complications in a multicentric study. Indian J. Pediatr. 1984; 51: 139-43.
20. Bellanti JA, Sangva RL, Klutinis B, Brant B, Arnestein MS. Antibody responses in serum and nasal secretions of children immunised with inactivated and attenuated measles virus vaccine. N. Engl. J. Med. 1969; 280: 628-33.
21. Bellini WJ, McFarlin DE, Silver GD, Mingioli ES, McFarland HF. Immune reactivity of the purified haemagglutinin of measles virus. Infect. Immun. 1981; 32: 1051-7.
22. Bhaskaram P, Radhakrishnan KV, Madhusudan J. Seroepidemiological study to determine age for measles vaccination. Indian J. Med. Res. 1986; 83: 480-6.
23. Bhatia R. Measles outbreak in village Tophema in Nagaland. J. Commun. Dis. 1985; 17(2): 185-9.

24. Bhatnagar SK, Mohan M, Kumar P, Balaja S, Prabhakar AK, Bhargava SK. Optimum age for measles immunisation, study of pre-and post-immunisation level of HI antibody titres. *Indian Pediatr.* 1981; 18: 625-9.
25. Bhau LNR, Madhavan HN, Agrawal SC. Serological survey of measles virus infection in children in Pondicherry area. *Indian J. Med. Res.* 1979; 69: 634-8.
26. Biviji TE, Shah PM, Udani PM. Physical growth and complications following measles in an urban community in Bombay. *Indian Pediatr.* 1972; 9(5): 265-8.
27. Black FL. Measles antibodies in the population of New Haven, Connecticut. *J. Immunol.* 1959; 83: 74-83.
28. Black FL, Sheridan SR. Studies on an attenuated measles virus vaccine. IV : Administration of vaccine by several routes. *N. Engl. J. Med.* 1960; 263(4): 165-9.
29. Black FL. Measles and mumps. *Manual of clinical immunology.* ASM Publication. Rose NR, Friedman H eds. 1976; 444-5.
30. Black FL, Berman LL, Libel M et al. Inadequate immunity to measles in children vaccinated at an early age : effect of revaccination. *Bull. WHO* 1984; 62(2): 315-9.
31. Blankson JM. Measles and its problems as seen in Ghana. *J. Trop. Pediatr.* 1975; 21: 51-4.
32. Borgono JM, Greiber R. Measles : a five year experience with a vaccination programme in Chile. In : *Proceedings of the International Conference on the application of vaccines against viral, rickettsial and bacterial diseases of man.* Scientific publication no. 226, Pan American Health Organisation, Washington D.C. 1971; 203-6.
33. Borgono JM. Current impact of measles in Latin America. *Rev. Infect. Dis.* 1983; 5(3): 417-21.
34. Boteler WL, Luipersbeck PM, Fuccillo DA, O'beirne AJ. Enzyme-linked immunosorbent assay for detection of measles antibody. *J. Clin. Microbiol.* 1983; 17 (5): 814-8.

35. Brandt EN Jr. Elimination of measles. JAMA. 1982; 248(23): 3093.
36. Breman JG, Coffi ER, Bombafre K, Foster SO, Herrmann KI. Evaluation of a measles-smallpox vaccination campaign by a seroepidemiologic method. Am. J. Epidemiol. 1975; 564-77.
37. Brinckner JAH. Proc. Roy. Soc. Med. 1938; 31: 807. As cited in 231.
38. British Research Committee. Second report on vaccination against measles. A clinical trial of live measles vaccine preceded by killed vaccine. Br. Med. J. 1968; 2: 449-52.
39. Broor S, Pal SR, Bannerjee AK, Chitkara NL, Choudhary S. Seroepidemiological study of measles virus infection in and around Chandigarh. Indian J. Med. Res. 1976; 64: 1740-6.
40. Brown JD. Studies of the measles immunisation status of children admitted to the pediatric observation ward of the Kenyatto National Hospital, Nairobi during Nov-Dec, 1976. East Afr. J. Med. 1977; 54: 531-4.
41. Brown P, Gajdusek DC, Tsai T. Persistence of measles antibodies in the absence of circulating natural virus five years after immunisation of an isolated virgin population with Edmonston-B vaccine. Am. J. Epidemiol. 1969; 90(6): 514-8.
42. Burrowes J, Cruickshank JG. At what age should measles vaccine be given? Central Afr. J. Med. 1976; 22: 45-7.
43. Buynak EB, Weibel RE, Whitman JE Jr., Stokes J Jr., Hillman MR. Combined live measles, mumps and rubella virus vaccines. JAMA. 1969; 207(12): 2259-62.
44. Campbell AGM. Measles immunisation : Why have we failed. Arch. Dis. Child. 1983; 58(1): 3-5.
45. Caronia G. Aetiologie and Prophylaxe de Masorn. Ergebn. d. inn. med. V. Kinderh. 1927; 32: 119-214. cf. Enders et al. Studies on attenuated measles virus vaccine. N. Engl. J. Med. 1960; 263(4): 153-9.
46. Centers for Disease Control. Morbidity and Mortality Weekly Rep. 1965; 14: 64-6.

47. Centers for Disease Control. Morbidity and Mortality Weekly Rep. 1971; 20: 115-6.
48. Centers for Disease Control. Recommendations of the US Public Health Service Advisory Committee on Immunisation Practices. Morbidity and Mortality Weekly Rep. 1976; 25: 359.
49. Centers for Disease Control. Recommendations of the Immunisation Practices Advisory Committee. Measles Prevention. Morbidity and Mortality Weekly Rep. 1982; 31(17): 217-36.
50. Centers for Disease Control. Measles prevention. Recommendations of the Immunisation Practices Advisory Committee. Morbidity and Mortality Weekly Rep. 1987; 36(26): 409-25.
51. Chalmers AK. The health of Glasgow, 1818-1825. Bell and Bain, Glasgow, 1930; 340.
52. Chandra RK. Reduced secretory antibody response to live attenuated measles and polio virus vaccines in malnourished children. Br. Med.J. 1975; 2: 583-5.
53. 'Charak Sanhita' - An Ayurvedic Text. As cited in 72.
54. Chawhan RN, Talib SH, Talib VH. A clinical profile of measles in Marathwada. A study of 115 cases. Indian J. Pediatr. 1976; 43(341): 172-7.
55. Chen LC, Chowdhary AKMA, Huffman SL. Anthropometric assessment of protein energy malnutrition and subsequent risk of mortality among pre-school age children. Am. J. Clin. Nutr. 1980; 33(8): 1836-45.
56. Cherian T, Abraham J, John TJ. Low antibody response in infants with measles and children with subclinical measles viral infection. J. Trop. Med. Hyg. 1984; 87: 27-31.
57. Cherry JD, Feigin RD, Lobes LA Jr. et al. Urban measles in the vaccine era : a clinical, epidemiologic and serologic survey. J. Pediatr. 1972; 81: 217-30.
58. Choudhry VP, Atmar M, Amin I, Aram GN, Ghani R. Effect of protein energy malnutrition on the immediate outcome of measles. Indian J. Pediatr. 1987; 54(5): 717-22.

59. Choudhury P. Practitioner's Column - Immunisation in children. *Indian Pediatr.* 1977; 14(1): 65-7.
60. Christie AB. *Infectious diseases : epidemiology and clinical practice.* Baltimore : Williams and Wilkins Co. 1969.
61. Cinfecu E. Serological survey of measles immunisation with the Rimevax - RIT vaccine in a Romanian district. *Arch. Rom. Patho. Exp.* 1980; 39: 31-9.
62. Convulsions and measles vaccination. In : Any questions ? *Br. Med. J.* 1969; 1: 696.
63. Coovadia HM, Wesley A, Brain P. Immunological events in acute measles influencing outcome. *Arch. Dis. Child.* 1978; 53: 861-7.
64. Currier RW, Hardy GE Jr., Conrad JL. Measles in previously vaccinated children : Evaluation of an outbreak. *Am. J. Dis. Child.* 1972; 124: 854-7.
65. Cutting WAM. Measles immunisation: A review. *J. Trop. Pediatr.* 1984; 30.
66. Danilov AI. The basis for vaccination against measles by aerosols of live vaccine. In : Hers JFP, Winkler KC, eds. *Airborne transmission and airborne infection.* John Wiley and Sons, New York. 1973; 344-5.
67. Dave KH. Efficacy of live measles vaccine in India. In : *Proceedings of the Smith Kline - RIT Symposium on potency and efficacy of vaccines,* Manila, Philippines. February 21-22, 1980.
68. Dave KH. Measles in India. *Rev. Infect. Dis.* 1983; 5(3): 406-10.
69. Davies JW, Acres SE, Varghese PV. Experience with measles in Canada and the United States. *Can. Med. Assoc. J.* 1982; 126(2): 123-5.
70. De Coto EML. Evolution of the measles vaccination programme in Costa Rica. *Rev. Infect. Dis.* 1983; 5(3): 588-91.
71. Desai AB, Shah C. Measles and its complications. *Indian Pract.* 1967; 20(3): 209-15.
72. Dholakia CR. A study on measles seropositivity and antibody response

- to measles immunisation. Dissertation submitted to M.S. University, Baroda for MD (Paed.) 1988.
73. Dick B. The provision of measles vaccine for an urban population. *South Afr. Med. J.* 1975; 49: 1507-13.
 74. Dick B, Smith T, Kipps A. A minimum age for measles vaccine administration to coloured children. *South Afr. Med. J.* 1975; 49: 1951-4.
 75. Dikshit SK, Gupta RC, Tandon L. Measles in infancy and childhood. *J. Indian Med. Assoc.* 1971; 56(8): 229-33.
 76. Dobyns HF. *Bull. Hist. Med.* 1963; 37: 493. As cited in 231.
 77. Dongre ST, Biranjan JR, Jalgaonkar SV, Polakhare JK. Measles antibody levels in 3-9 month old infants. *Indian Pediatr.* 1989; 26(8): 775-9.
 78. Dosseter J, Whittle HC, Greenwood BM. Persistent measles infection in malnourished children. *Br. Med. J.* 1977; 1: 1633-5.
 79. Dubowitz L, Dubowitz V. Assessment of gestational age at birth. In : *Nelson's Textbook of Pediatrics*. 13th ed. Nelson WE, Behrman RE, Vaughan VC eds. Philadelphia. WB Saunders Company. 1987; 376-8.
 80. Dudgeon JA. Measles vaccines. *Br. Med. Bull.* 1969; 25(2): 151-8.
 81. Dudgeon JA. Measles and rubella vaccines. *Arch. Dis. Child.* 1977; 52: 907-11.
 82. Dudgeon JA. Prospects for worldwide control of measles. Discussion II. *Rev. Infect. Dis.* 1983; 5(3): 621-2.
 83. Dutta AK, Singhal PK, Khare S, Kumari S, Mathur R, Mullick DN. Immune status following measles vaccination in infants and evaluation for the need of revaccination. *Indian Pediatr.* 1989; 26(8): 765-8.
 84. Eddy KC Lo, Nafisah bt. Ali Hussein. Measles in Malaysia. A brief report of the 1981 antimeasles pilot study. *Rev. Infect. Dis.* 1983; 5(3): 405.
 85. Editorial. *Am. J. Pub. Health.* 1983; 73(5): 490-1.
 86. Ekunwae. Malnutrition and seroconversion following measles immunisation. *J. Trop. Pediatr.* 1985; 31: 290-1.

87. Enders JF, Peebles TC. Propagation in tissue cultures of cytopathogenic agents from patients with measles. *Proc. Soc. Exp. Biol. Med.* 1954; 86: 277-86.
88. Enders JF, Katz SL, Milovanovic MV, Hollaway A. Studies on an attenuated measles virus vaccine. I. Development and preparation of the vaccine: techniques for assay of effects of vaccination. *N. Engl. J. Med.* 1960; 263: 153-84.
89. Enders JF. Measles virus. *Am. J. Dis. Child.* 1962; 103(3): 282-6.
90. Expanded Programme on Immunisation. Measles immunisation. *Wkly. Epidem. Rec.* 1979; 54: 337-9.
91. Expanded Programme on Immunisation. Stability of freeze-dried measles vaccine. *Wkly. Epidem. Rec.* 1981; 56: 177-9.
92. Expanded Programme on Immunisation. Seroconversion rate after measles vaccination. *Wkly. Epidem. Rec.* 1981; 56: 233-40.
93. Expanded Programme on Immunisation. The optimal age for measles immunisation. *Wkly. Epidem. Rec.* 1982; 57: 89-91.
94. Feachem RG, Koblinsky MA. Interventions for the control of diarrhoeal diseases among young children : Measles immunisation. *Bull. WHO.* 1983; 61(4): 641-52.
95. Foege WH. Banishing measles from the world. *World Health Forum.* 1984; 5(1):63-4.
96. Fox JP, Elveback LR. Herd immunity - changing concepts. In : Notkins AL ed. *Viral Immunology and Immunopathology.* Academy Press, New York. 1975; 273-90.
97. Fox JP. Herd immunity and measles. *Rev. Infect. Dis.* 1983; 5(3): 463-6.
98. Fulginiti VA. Immunisation - current controversies. *J. Pediatr.* 1982; 101(4): 487.
99. Garai R, Chakraborty AK. Measles in a rural community. *Indian J. Public Health.* 1980; 24(3): 150-3.

100. Ghosh S, Dhatt PS. Complications of measles. *Indian J. Child Health.* 1961; 10: 111-9.
101. Ghosh S, Kumari S, Bhargava SK. Antibody titres after measles vaccination. *Indian J. Med. Res.* 1977; 66(2): 65-71.
102. Gordon JE, Jansen AA, Ascoli W. Measles in rural Guatemala. *J. Pediatr.* 1965; 66: 779-86.
103. Gould MK. Hot, cold, clean, poison and dirt: Chinese folk medical categories. *Soc.Sci.Med.* 1978; 1213: 39-45.
104. Griffith AH. Measles vaccination in tropical countries. *Trans. R. Soc. Trop. Med. Hyg.* 1975; 69: 29-30.
105. Gunby P. Complications of measles: potentially devastating. In: *Measles immunisation. Medical news. JAMA.* 1978; 240(25): 2714-5.
106. Gupta BP. An experience with measles vaccine in India. *Indian J. Pediatr.* 1984; 51: 403-5.
107. Gupta SC. *Social science and medicine.* 1970; 4: 65.
108. Hafez MGH, Aref, Mehareb SW et al. Antibody production and complement system in protein energy malnutrition. *J.Trop.Med.Hyg.* 1977; 80: 36-8.
109. Halsey NA. The optimal age for administering measles vaccine in developing countries. *Recent advances in immunisation.* 1983: 4-17.
110. Halsey NA, Boulos R, Mode F et al. Response to measles vaccine in Haitian infants 6-12 months old: Influence of maternal antibodies, malnutrition and current illness. *N. Engl. J. Med.* 1985; 313: 544-9.
111. Hayden RJ. Reduced dosage measles vaccination trial in Nairobi. *East Afr.Med.J.* 1972; 49: 213-8.
112. Hayden RJ. The epidemiology and nature of measles in Nairobi before the impact of measles immunisation. *East Afr. Med. J.* 1974; 51: 199-205.
113. Hektoen L. Experimental measles. *J. Infect. Dis.* 1905; 2: 238. As cited in 89.

114. Henderson DA. Global measles eradication. *Lancet*. 1982; *i*: 208.
115. Henderson RH. Primary health care as a practical means for measles control. *Rev. Infect. Dis.* 1983; 5(3): 592-5.
116. Henderson RH. Director, EPI, WHO global overview: The EPI protecting the world's children: "Bellagio II" at Cartagena, Columbia, October 1985: A joint WHO, UNICEF, World Bank, UNDP and Rockefeller Foundation Conference Report.
117. Hendrickse RG, Montefiere D, Peradze T, Sherman P, Powell M. Measles vaccination. Report of a large scale trial of further attenuated measles vaccine in Nigeria. *J. Trop.Med.Hyg.* 1966; 69: 112-6.
118. Hendrickse RG, Montefiere D. Measles vaccination with reduced dosage. *Br. Med. J.* 1968; 4: 28-30.
119. Hendrickse RG. Problems of future measles vaccination in developing countries. *Trans. R. Soc. Trop. Med. Hyg.* 1975; 69(1): 31-2.
120. Herman JJ, Radin R, Schneiderman R. Allergic reactions to measles (rubeola) vaccine in patients hypersensitive to egg protein. *J. Pediatr.* 1983; 102(2): 196-9.
121. Heymann DL, Nakano JH, Maben GK, Durand B. Field trials of a heat stable measles vaccine in Cameroon. *Br. Med. J.* 1979; 2: 99-100.
122. Heymann DL, Smith EL, Nakano JH, Jato JG, Martin GE, Maben GK. Further field testing of the more heat stable measles vaccine in Cameroon. *Br. Med. J.* 1982; 285(21): 531-3.
123. Hilleman MR, Buynak EB, Weibel RE, Stokes J Jr., Whitman JE JR., Leagus MB. Development and evaluation of the Moraten measles virus vaccine. *JAMA.* 1968; 206: 587-90.
124. Hilleman MR, McAleer WJ. Vaccine delivery system. US Patent Office, no. 4,022,206. 1977.
125. Hilleman MR, McAleer WJ, McLean AA, Buynak EB, Markus HZ. Stabilised measles vaccine in a novel single dose delivery system. A practical reality for worldwide elimination of measles. *Rev. Infect. Dis.* 1983; 5(3): 511-3.

126. Hinman AR, Orenstein WA, Bloch AB et al. Impact of measles in the United States. *Rev. Infect. Dis.* 1983; 5(3): 439-44.
127. Hinman AR, Kirby CD, Eddins DL et al. Elimination of indigenous measles from the United States. *Rev. Infect Dis.* 1983; 5(3): 538-45.
128. Hirsch A. *Handbook of Graphical and Historical Pathology*. Translated by Creighton C, London. The New Sydenham Society, (1883). As cited in 234.
129. Home F. *Medical Facts and Experiments*. A Millar. London, 1749. As cited in 88.
130. Hopkins DR, Koplan JP, Hinman AR, Lane JM. The case for global measles eradication. *Lancet*. 1982; 1: 1396-8.
131. Hull HF, Williams PJ, Oldfield F. Measles mortality and vaccine efficacy in rural West Africa. *Lancet*. 1983; 2: 972-5.
132. Ifekwunigwe AE, Grasset N, Glass R, Foster S. Immune response to measles and smallpox vaccination in malnourished children. *Am. J. Clin. Nutr.* 1980; 33: 621-4.
133. Ikic DM. Edmonston-Zagreb strain of measles vaccine: Epidemiologic evaluation in Yugoslavia. *Rev. Infect. Dis.* 1983; 5(3): 558-63.
134. *Issues in World Health. Population Reports*. 1986; 5: L-157-9.
135. Jajoo UN, Chabra S, Gupta OP, Jain AP. Feasibility of measles vaccine. Experience with live attenuated virus vaccine in and around Sevagram. *Indian J. Pediatr.* 1983; 50(405): 379-81.
136. James HO, West CE, Duggan MB, Ngwa M. A controlled study on the effect of injected water miscible retinyl palmitate on plasma concentrations of retinol and retinol binding protein in children with measles in Northern Nigeria. *Acta Pediatr. Scand.* 1984; 73: 22-8.
137. Jaspal D, Krishnadas MS, Rashmi A, Khatri RL, Guha DK. Increasing severity of measles: a critical analysis of 200 hospitalised cases. *Indian Pediatr.* 1978; 15(9): 719-24.
138. Job JS, John TJ, Joseph A. Antibody response to measles immunisation in India. *Bull. WHO.* 1984; 62(5): 737-41.

139. John TJ, Devrajan LV. Priority for measles vaccine (Editorial). Indian Pediatr. 1973; 10(2): 57-8.
140. John TJ, Jesudoss ES. A survey of measles antibody in children. Indian Pediatr. 1973; 10(2): 65-6.
141. John TJ, Joseph A, George TI, Radhakrishnan J, Singh RPD, George KJ. Epidemiology and prevention of measles in rural South India. Indian J. Med. Res. 1980; 72: 153-8.
142. John TJ, Steinhoff MC. Strategy for childhood immunisation in India. I. Prioritisation of vaccines. Indian J. Pediatr. 1980; 47(389): 463-6.
143. John TJ. Optimum age for measles immunisation. Indian Pediatr. 1982; 19(5): 455-6.
144. John TJ. Symposium : Infectious diseases. Measles in India, a neglected problem. Indian J. Pediatr. 1983; 50(405): 399-403.
145. John TJ. Measles. Future. 1985; 17: 39-46.
146. John TJ, Selvakumar R. Mixing measles vaccine with DPT and DPTP. Lancet. 1985; 1: 1154.
147. Johnson RT, Griffin DE, Hirsch RL et al. Measles encephalomyelitis - clinical and immunologic studies. N. Engl. J. Med. 1984; 310(3): 137-41.
148. Jordan WS. Measles immunisation: Remaining needs for research. Rev. Infect. Dis. 1983; 5(3): 613-8.
149. Joseph A, Jayakaraman. High priority for measles vaccination; a Workshop at CMC, Vellore.
150. Kantharia SL. Clinical and serological trial of measles vaccine and study of social factors in epidemiology of measles. Dissertation submitted to South Gujarat University for MD(PSM), 1982.
151. Katiyar GP, Kaur G, Agrawal DK, Gulati AK, Kalra A, Agarwal KN. Sero-conversion response to Mevelin-L measles vaccine at age 6-15 months. Indian Pediatr. 1985; 22(8): 653-9.

152. Katz SL, Milovanovic MV, Enders JF. Propagation of measles virus in cultures of chick embryo cells. *Proc. Soc. Exp. Biol. Med.* 1958; 97: 23-9.
153. Katz S, Enders JF. Immunisation of children with a live attenuated measles virus. *Am. J. Dis. Child.* 1959; 85: 605-7.
154. Katz SL, Morley DC, Krugman S. Attenuated measles vaccine in Nigerian children. *Am. J. Dis. Child.* 1962; 103(3): 402-5.
155. Katz SL. Summary of current status of measles and recommendations. *Rev. Infect. Dis.* 1983; 5(3): 623-4.
156. Katz S. Measles forgotten but not gone. *N. Engl. J. Med.* 1985; 313(9): 577-8.
157. Kaur G. Maternal and cord blood measles antibody titres. *Indian J. Med. Res.* 1982; 76: 407-14.
158. Kaur G, Gulati AK, Agrawal DK, Katiyar GP, Kalra, Agrawal KN. A study on post measles vaccine seroconversion. *Indian J. Med. Microbiol.* 1984; 2(2): 131-6.
159. Kempe CH, Ott EW, Vincent St. L, Maisel JC. Studies on attenuated measles virus vaccine. III. Clinical and antigenic effects of vaccine in institutionalised children. *N. Engl. J. Med.* 1960; 162-5.
160. Kempe CH. Measles vaccine in children with asthma and tuberculosis. *Am. J. Dis. Child.* 1962; 103(3): 409.
161. Khanum S, Garelick H, Nasiruddin, Mann G, Tomkins A. Comparison of Edmonston-Zagreb and Schwarz strains of measles vaccine given by aerosol or subcutaneous injection. *Lancet.* 1987; 1: 150-4.
162. Khare S, Dutta A, Kumari S, Basu RN. Seroepidemiology of measles in Delhi: implications for age of vaccination. *Indian J. Pediatr.* 1987; 54(5): 711-5.
163. Kimati VP, Loretu K, Munube GMR, Kimboi F. Measles vaccination. The problem of measles virus response with reference to vaccine viability, age, protein energy malnutrition and malaria in the tropics. *J. Trop. Pediatr.* 1981; 27(4): 205-9.

164. King B. Measles vaccination in rural Tanzanian community. *East Afr. Med. J.* 1978; 55: 252-5.
165. Kipps A, Dick G, Moodie JW. Measles and the CNS. *Lancet.* 1983; 2: 1406-10.
166. Kok PW, Kenya PR, Ensering H. Measles immunisation with further attenuated heat stable measles vaccine using five different methods of administration. *Trans. R. Soc. Trop. Med. Hyg.* 1983; 77(2): 171-6.
167. Koster FT, Curlin GC, Aziz KMA, Haque A. Synergistic impact of measles and diarrhoea on nutrition and mortality in Bangladesh. *Bull. WHO.* 1981; 59(6): 901-8.
168. Krause PJ, Cherry JD, Naiditch MJ, Deseda-Tous J, Walbergh EJ. Revaccination of previous recipients of killed measles vaccine: clinical and immunologic studies. *J. Pediatr.* 1978; 93: 565-71.
169. Kress S, Schluederberg AE, Hornick RB et al. Studies with live attenuated measles virus vaccine. II. Clinical and immunologic response of children in an open community. *Am. J. Dis. Child.* 1961; 101(6): 701-7.
170. Krishnamurthy KA, Anantharaman V. Measles, a dangerous disease: a study of 1000 cases in Madurai. *Indian Pediatr.* 1974; 11(4): 267-71.
171. Krugman S, Giles JP, Friedman H, Stone S. Studies on immunity to measles. *J. Pediatr.* 1965; 66(3): 471-88.
172. Krugman S, Giles JP. Measles. The problem. In: *Proceedings of the Pan American Health Organisation Conference on the application of vaccines against viral, rickettsial and bacterial diseases of man.* Pan American Health Organisation Scientific Publication No. 226. Washington DC. 1971; 195-202.
173. Krugman S. Present status of measles and rubella immunisation in the United States: A medical progress report. *J. Pediatr.* 1971; 78(1): 1-16.
174. Krugman S. Measles immunisation: New recommendations. *JAMA.* 1977; 237(4): 366.

175. Krugman S. Present status of measles and rubella immunisation in the United States: A medical progress report. *J. Pediatr.* 1977; 90(1): 1-12.
176. Krugman S, Rosenberg R, McIntosh K et al. Further attenuated live measles vaccines: the need for revised recommendations. *J. Pediatr.* 1977; 91: 766-7.
177. Krugman S, Katz SL. *Infectious diseases of children*. 7th ed. CV Mosby, St. Louis. 1981.
178. Krugman S, Katz SL, Quinn TC. Preface. *Rev. Infect. Dis.* 1983; 5(3): 389-90.
179. Krugman S. Further attenuated measles vaccine: characteristics and use. *Rev. Infect. Dis.* 1983; 5(3): 477-81.
180. Kumar R, Chandra R, Bhushan V, Srivastava BC. Adverse reactions after measles immunisation in a rural population. *Indian Pediatr.* 1982; 19(7): 605-10.
181. Lampe R, Wier MR, Scott RM et al. Measles reimmunisation in children immunised before one year of age. *Am. J. Dis. Child.* 1985; 139: 33-5.
182. Larke RPB. Impact of measles in Canada. *Rev. Infect. Dis.* 1983; 5(3): 445-51.
183. Lee YL, Black FL, Chen CL, Wu CL, Berman LL. The optimal age for vaccination against measles in an Asiatic city, Taipei, Taiwan. Reduction of vaccine induced titre by residual transplacental antibody. *Int. J. Epidemiol.* 1983; 12(3): 340-3.
184. Levy DL. The future of measles in highly immunised populations. A modeling approach. *Am. J. Epidemiol.* 1984; 120(1): 39-48.
185. Lin CY, Hsu HC. Measles and acute glomerulonephritis. *Pediatrics.* 1983; 71(3): 398-401.
186. Linnemann CC Jr., Rotte TC, Schiff GM, Youtsey JL. A seroepidemiologic study of a measles epidemic in a highly immunised population. *Am. J. Epidemiol.* 1972; 95(3): 238-46.

187. Linnemann CC Jr, Dine MS, Bloom JE, Schiff GM. Measles antibody in previously immunised children: the need for revaccination. *Am. J. Dis. Child.* 1972; 124: 53-7.
188. Linnemann CC. Measles Vaccine: immunity, reinfection and revaccination. *Am. J. Epidemiol.* 1973; 97(6): 365-71.
189. Linnemann CC, Shea L, Elsen W. et al. Serum survey of urban school children for antibodies to immunisable diseases. *Clin. Res.* 1973; 21: 464.
190. Linnemann CC Jr., Dine MS, Roselle GA et al. Measles immunity after revaccination: Results in children vaccinated before 10 months of age. *Pediatrics.* 1982; 69: 332-5.
191. Lobo J, Reddaiah VP, Kapoor SK, Nath LM. Epidemiology of measles in a rural community. *Indian J. Pediatr.* 1987; 54(2): 261-5.
192. Loenning WKK, Coovadia HN. Age specific occurrence rates of measles in urban, peri-urban and rural environment: implications for time of vaccination. *Lancet.* 1983; 2: 324-6.
193. Lundbeck H, Block AB. Concluding session: Summary. *Rev. Infect. Dis.* 1983; 5(3): 625.
194. 'MADHAVNIDAAAN' - An Ayurvedic text. As cited in 72.
195. Maina B, Ahlberg. Beliefs and practices concerning treatment of measles and acute diarrhoea among the Akamber. *Trop. Geog. Med.* 1979; 31: 139-40.
196. Makino S. Development and characteristics of live AIK-C measles virus vaccine: A brief report. *Rev. Infect. Dis.* 1983; 5(3): 504-5.
197. Malik A, Ghosh PB, Shukla I, Malik MA. Measles immunity and the optimum age for vaccination. *Indian Pediatr.* 1989; 26(8): 769-72.
198. Mandara MP, Remme J. Current measles control in Tanzania. *Rev. Infect. Dis.* 1983; 5(3): 554-7.
199. Man Mohan, Mehta PK, Sehgal S, Prabhakar AK, Bhargava SK. Optimum age of measles immunisation. Maternal and transplacentally transmitted measles antibodies in infancy. *Indian Pediatr.* 1981; 18(9): 631-5.

200. Man Mohan, Sehgal SK. Optimal age for measles vaccination. Editorial. *Indian Pediatr.* 1989; 26(8): 739-42.
201. Mann GF. New approaches to the practical problems of measles vaccine. Proceedings of symposium on stability and effectiveness of measles, poliomyelitis and pertussis vaccines. Yugoslav Academy of Sciences and Arts. Zagreb. 1976.
202. Marks JS, Halpin TJ, Orenstein WA. Measles vaccine efficacy in children previously vaccinated at 12 months of age. *Pediatrics.* 1978; 62(6): 955-60.
203. Marshall RJ, Habicht JP, Landrigan PJ, Foege WH, Delgado H. Effectiveness of measles vaccine given simultaneously with DPT. *J. Trop. Pediatr.* 1974; 20: 126-9.
204. Mathews T, Jadhav M, John TJ. Measles in well nourished children. *Indian Pediatr.* 1971; 8(2): 68-70.
205. McAleer WJ, Markus HZ, McLean AA, Buynak EB, Hilleman MR. Storage at various temperatures of live measles, mumps and rubella virus vaccines in new stabiliser. *J. Biol. Stand.* 1980; 8: 281-7.
206. McAleer WJ, Markus HZ, Buynak EB et al. A novel single dose delivery system for vaccines. *J. Biol. Stand.* 1982; 10: 329-33.
207. McCrumb FR Jr., Hornick RB, Kress S et al. Studies with live attenuated measles virus vaccine. III. Development of a practical method for large scale immunisation. *Am. J. Dis. Child.* 1961; 101(6): 708-12.
208. McEwen J. Early onset reaction after measles vaccination: Further Australian reports. *Med. J. Aust.* 1983; 2(10): 503-5.
209. McGraw MD, Terrence TT. Reimmunisation following early immunisation with measles vaccine: A prospective study. *Pediatrics.* 1986; 77: 45-8.
210. McIntyre RC, Preblud SR, Pilliri A, Korean M. Measles and measles vaccine in a remote island population. *Bull. WHO.* 1982; 60(5): 767-75.
211. McMurray PN, Loomis SA, Casazza LJ, Rey H. Influence of moderate malnutrition on morbidity and antibody response following vaccination

- with live attenuated measles virus vaccine. Bull. Pan Am. Health Organ. 1979; 13: 52-7.
212. Measles. In : Laboratory Diagnosis of Viral Infections. Lennette EH, ed. New York and Basel Marcel Dekker Inc. 1982; 359-67.
 213. Measles and Indians. Editorial. Br. Med. J. 1982; 285: 1762-3.
 214. Measles immunisation: New recommendations. Committee on Infectious Diseases of the American Academy of Pediatrics. 1978.
 215. Measles Immunisation Project. EPI Section. Directorate General of Health Services, Government of India, New Delhi. First Reprint. 1982.
 216. Measles in the tropics. Br. Med. J. 1976; 2: 1339-40.
 217. Measles Sub-Committee of the Committee on Development of Vaccines and Immunisation Procedures. Fourth report to the Medical Research Council. Clinical trial of live measles vaccine given alone and live vaccine preceded by killed vaccine. Lancet. 1977; 2: 571-5.
 218. Meera R. A clinical study of reactions to live measles virus vaccine in malnourished and well nourished children: Thesis for the degree of M.D.(Paed.); Univ. of Delhi, 1978.
 219. Mehta NA, Nanavati AND, Jhala M, Sant MV. Seroepidemiology of measles in Bombay. Indian J. Med. Res. 1972; 60: 661-9.
 220. Merz DC, Scheid A, Choppin PW. Importance of antibodies to the fusion glycoprotein of paramyxoviruses in the prevention of spread of infection. J. Exp. Med. 1980; 151: 275-88.
 221. Meulen V, Hall WW, Kreth HW. Pathogenetic aspects of subacute sclerosing panencephalitis. In: Stevens JG, Todaro GJ, Fox CF, eds. Persistent viruses. Vol. XI. Academic Press, New York. 1978; 615-34.
 222. Meyer HM, Hostetler DD, Bernheim BL et al. Response of Volta children to live attenuated measles vaccine. Bull. WHO. 1964; 30: 769-81.
 223. Ministries of Health of Brazil, Chile, Costa Rica and Equador and the Pan American Health Organisation. Seroconversion rates and measles antibody titres induced by measles vaccination in Latin American children 6-12 months of age. Rev. Infect. Dis. 1983; 5(3): 596-605.

224. Ministry of Health and Family Welfare: Manual on Immunisation, Directorate of Advertising and Visual Publicity, New Delhi, 1978.
225. Mirchamsy H, Shafyi A, Mahinpour M, Nazari P. Age of measles immunisation in tropics. *Dev. Biol. Stand.* 1978; 41: 191-4.
226. Mirchamsy H. Measles immunisation in Iran. *Rev. Infect. Dis.* 1983; 5(3): 491-4.
227. Mitchell CD, Balfour HH. Measles Control: so near yet so far. In : *Progress in Medical virology*. Karger AG ed. Switzerland. 1985. 1-37.
228. Mittal SK, Gulati A, Kumari P, Vijayabala, Gupta S. Seroconversion following measles immunisation. *Indian Pediatr.* 1979; 16(4): 309-11.
229. Morley D, Woodland M, Martin WJ. Measles in Nigerian children. A study of the disease in West Africa and its manifestations in England and other countries during different epochs. *J. Hyg. (Lond).* 1963; 61: 115-34.
230. Morley D, Martin WJ, Allen I. Measles in East and Central Africa. *East Afr. Med. J.* 1967; 44: 12.
231. Morley D. Severe Measles in Tropics-I. *Br. Med. J.* 1969; 1: 297-300.
232. Morley D. Severe Measles in Tropics-II. At what age should measles vaccine be given ? *Br. Med. J.* 1969; 1: 363-5.
233. Morley D. Measles in the developing world. *Proc. Roy. Soc. Med.* 1974; 67: 1112-5.
234. Morley D. Pediatric priorities in the developing world. Butterworth, London. 1977; 207-31.
235. Munyer TP, Mangi RJ, Dolan T, Kantor FS. Depressed lymphocyte function after MMR vaccination. *J. Infect. Dis.* 1975; 32(1): 75-8.
236. Murphy MD, Brunell PA, Lievens AW et al. Effect of early immunisation on antibody response to reimmunisation with measles vaccine as demonstrated by enzyme-linked immunosorbent assay (ELISA). *Pediatrics.* 1984; 74: 90-3.

237. Nader PR, Horwitz MS, Rosseau J. Atypical exanthem following exposure to natural measles: eleven cases in children previously inoculated with killed vaccine. *J. Pediatr.* 1968; 72: 22-8.
238. Naficy K, Nategh R. Measles vaccine and its uses in developing countries. *Advances in Virus Research.* 1972; 17: 279-92.
239. Nanavaty AND, Mehta NA. Measles surveys. *Bull. WHO.* 1972; 47: 673-4.
240. National Advisory Committee on Immunisation. Further statement on elimination of indigenous measles in Canada. *Canada Diseases Weekly Rep.* 1981; 7: 81-2.
241. Natu M, Chavan H, Ratnanidhi A. Measles vaccination. *Indian Pediatr.* 1985; 22(8): 597-600.
242. Nelson WE, Behrman RE, Vaughan VC comps. *Nelson Textbook of Pediatrics.* 13th ed. Philadelphia. W.B. Saunders Company. 1987; 655-8.
243. Nigam P, Tandon VK, Sahai I et al. A clinical study of measles. *Indian J. Pediatr.* 1973; 40(301): 54-7.
244. Nkowane BM, Bart SW, Orenstein WA, Baltier M. Measles outbreak in a vaccinated school population. Epidemiology, chains of transmission and role of vaccine failures. *Am. J. Public Health.* 1987; 77(4): 434-8.
245. Noah ND. What can we do about measles? Editorial. *Br. Med. J.* 1984; 289: 1476.
246. Norrby E. Haemagglutination by measles virus. IV. A simple procedure for production of high potency antigen for haemagglutination inhibition (HI) tests. *Proc. Soc. Exp. Biol. Med.* 1962; 111: 814-8.
247. Norrby E. Haemagglutination by measles virus. III. Identification of two different haemagglutinins. *Virology.* 1963; 19: 147.
248. Norrby E. Occurrence of antibodies against envelope components after immunisation with formalin inactivated and live measles vaccines. *J. Biol. Stand.* 1975; 3: 375-80.
249. Nutrition Subcommittee of the Indian Academy of Pediatrics. Report of the convenor. *Indian Pediatr.* 1972; 9: 360.

250. Okuno Y. Vaccination with egg passage measles virus by inhalation. *Am. J. Dis. Child.* 1962; 103: 381-4.
251. Panum PL. Observations made during the epidemic of measles on the Faroe Islands in the year 1846. *Medical Classics*, Baltimore and Wilkins; 3: 1938-9. As cited in 72.
252. Peetermans J, Colinet G, Stephenne J. Activity of attenuated poliomyelitis and measles vaccines exposed at different temperatures. *Proceedings of the Symposium on stability and effectiveness of measles, poliomyelitis and pertussis vaccines.* 1976; 61-6.
253. Perkins FT. Measles vaccines: Discussion. *Rev. Infect. Dis.* 1983; 5(3): 531.
254. Phadke MA, Rodrigues JJ, Mehta JM, Ayachit V. Clinical and serological evaluation of live measles vaccine in India. *Indian Pediatr.* 1983; 20: 573-6.
255. Plotkin SA, Farquhar JD. Immunity to rubella: comparison between naturally and artificially induced resistance. *Post Grad. Med. J.* 1972; 47-51.
256. Pov KM. Measles: the epidemiology and control of an outbreak. *J. Am. College Health.* 1983; 31(4): 158-61.
257. Powell GM. Response to live attenuated measles vaccine in children with severe kwashiorkor. *Ann. Trop. Pediatr.* 1982; 2(3): 143-5.
258. Preblud SR, Gross F, Halsey NA, Hinman AR, Herrmann KL, Koplan JP. Assessment of susceptibility to measles and rubella. *JAMA.* 1982; 247(8): 1134-7.
259. Puffer RP, Serrano CV. Patterns of mortality in childhood. Scientific publication No. 262. Pan American Health Organisation, Pan American Sanitary Bureau. Regional Office of the WHO, Washington, D.C. 1973.
260. Pulmonary complications of measles. *Br. Med. J.* 1976; 2: 777-8.
261. Rake G, Shaffer MF. Studies on measles. I. The use of chorio-allantois of the developing chick embryo. *J. Immun.* 1940; 38: 177.
262. Ramakrishnan K. Measles: A clinical study of 60 cases. *Indian Pediatr.* 1978; 15(12): 1035-7.

263. Rashmi A, Guha DK, Khanduja PC. Post measles pulmonary complications in children. *Indian Pediatr.* 1971; 8(12): 834-8.
264. Rawls WE, Rawls ML, Chernesky MA. Analysis of a measles epidemic; possible role of vaccine failures. *Can. Med. Assoc. J.* 1975; 113: 941-4.
265. Reddy V. Interaction between nutrition and measles. *Indian J. Pediatr.* 1987; 54(1): 53-7.
266. Reilly CM, Stokes J, Buynak EB, Goldner H, Hilleman MR. Live attenuated measles virus vaccine in early infancy: Studies on the role of passive antibody in immunisation. *N. Engl. J. Med.* 1961; 265: 165-9.
267. Rey M. WHO Consultant to Government of India. Measles and measles vaccination in India. WHO South East Asia Region. Assignment report 1979.
268. Rey M, Celers J, Mouton Y, Netter R. Impact of measles in France. *Rev. Infect. Dis.* 1983; 5(3): 433-8.
269. Reynolds DW, Stuart A. Immunity to measles in children vaccinated before and after one year of age. *Am. J. Dis. Child.* 1972; 124: 848-50.
270. Rhazes. On the smallpox and measles, 850 A.D. *Diviso Morborum.* 149, London, Sydenham Society, 1848. As cited in 89.
271. Richmond JB. Measles elimination: Why not now? *JAMA.* 1979; 242(11): 1175.
272. Robbins FC. Prospects for world-wide control of measles. Discussion I. *Rev. Infect. Dis.* 1983; 5(3): 619-20.
273. Roberts CM. The short term effects of a measles vaccination programme on a rural Nigerian community. *J. Trop. Pediatr.* 1984; 30(3): 184-8.
274. Rosen L. Haemagglutination and haemagglutination inhibition with measles virus. *Virology.* 1961; 13: 139-41.
275. ROUVAX. Thermostat vaccine against measles. Product information. Institut Merieux. France.
276. Ruben FL, Smith EA, Foster SL et al. Simultaneous administration

- of small pox, measles, yellow fever and DPT antigens to Nigerian children. Bull. WHO. 1973; 48: 175-81.
277. Sabin AB, Castro JF, Arechiga AF, Sever JL, Madden DL, Shekarchi I. Clinical trials of inhaled aerosol of human diploid cell and chick embryo measles vaccines. (Letter). Lancet 1982; 2: 604.
 278. Sabin AB, Arechiga AF, Castro JF et al. Successful immunisation of children with and without maternal antibody by aerosolised measles vaccine. I. Different results with undiluted human diploid cell and chick embryo fibroblast vaccines. JAMA. 1983; 249(19): 2651-62.
 279. Sabin AB. Immunisation against measles by aerosol. Rev. Infect. Dis. 1983; 5(3): 514-23.
 280. Sabin AB, Arechiga AF, Castro JF, Albrecht P, Sever JL, Shekarchi I. Successful immunisation of infants with and without maternal antibody by aerosolised measles vaccine. II. Vaccine comparisons and evidence for multiple antibody response. JAMA. 1984; 251(18): 2363-71.
 281. Saha SM. Draft Manual for serology in measles. Personal communication.
 282. Saha SM, Balasubramaniam N, Kadhu BS. Seroepidemiological diagnosis of measles in India. Indian J. Pathol. Microbiol. 1980; 23: 231-34.
 283. Saha SM, Aggarwal RK, Sood DK, Saxena SK. Seroconversion in different age groups after measles vaccination. Indian J. Pediatr. 1985; 52(416): 303-5.
 284. Saha SM, Aggarwal RK, Sood DK, Chakravarty S, Saxena SN. The cold chain in the measles immunisation programme in India. Indian J. Pediatr. 1988; 55(3): 356-8.
 285. Salunke SR, Natu M. Epidemiological investigation of measles - an outbreak at Ajivali. Indian Pediatr. 1977; 14(7): 519-22.
 286. Sandford-Smith JH, Whittle HC. Corneal ulceration following measles in Nigerian children. Br.J.Ophthal. 1979; 63: 720-4.
 287. Sasson A. Medicine and Public Health in Biotechnology and Development. UNESCO. Technical centre for agricultural and rural co-operation. 1988; 149.

288. Scheifele DW, Forbes CE. Prolonged giant cell excretion in severe African measles. *Pediatrics*. 1972; 50: 867-73.
289. Schluederberg A, Lamm SH, Landrigan PJ, Black FL. Measles immunity in children vaccinated before one year of age. *Am. J. Epidemiol.* 1973; 97(6): 402-9.
290. Schwarz AJF, Boyer PA, Zirbel LW, York CJ. Experimental vaccination against measles. I. Tests of live measles and distemper vaccine in monkeys and two human volunteers under laboratory conditions. *JAMA*. 1960; 173(8): 861-7.
291. Schwarz AJF. Immunisation against measles. Development and evaluation of a highly attenuated measles vaccine. *Annales de pediatrie*. 1964; 202: 241-52.
292. Schwarz T, Klingberg W, Nishmi M et al. Comparative study of four live measles vaccines in Israel. *Bull. WHO*. 1968; 39: 285-92.
293. Sehgal S, Sharma RB, Mehta PK, Sebastian M, Arora RR. Seroepidemiological survey of measles. *J. Commun. Dis.* 1983; 15(1): 1-7.
294. Sehgal S, Sharma RB, Das A, Sebastian M, Arora RR. Seroconversion after measles vaccination in infants and children. *J. Commun. Dis.* 1983; 15(2): 75-9.
295. Shah DN. Felt need, impact and evaluation of ICDS programme in a tribal block. *Ann. Nati. Med. Sci.* 1983; 19: Jan-Mar.
296. Shah U, Bannerji KL, Nanavati AND, Mehta NA. A test survey of measles in a rural community in India. *Bull. WHO*. 1972; 46(1): 130-8.
297. Shah U, Aphale AV, Nanavati AND. Measles vaccination in a rural area. *Indian J. Medi. Sci.* 1972; 26(4): 221-5.
298. Shahid NS, Rahman ASMM, Aziz KMA, Faruque ASG, Bari MA. Beliefs and treatment related to diarrhoeal episodes reported in association with measles. *Trop. Geog. Med.* 1983; 35: 151-6.
299. Sharma RS, Kaushik VK, Johri SP, Rai SN. Epidemiological investigation of measles outbreak in Alwar in Rajasthan. *J. Commun. Dis.* 1984; 16(4): 299-303.

300. Shasby DM, Shope TC, Downs H, Herrmann KL, Polkowski. Epidemic measles in a highly vaccinated population. *N. Engl. J. Med.* 1977; 269: 585-9.
301. Shelton JD, Jacobson JE, Orenstein WA, Schulz KF, Donnell HD. Measles vaccine efficacy: influence of age at vaccination vs. duration of time since vaccination. *Pediatrics.* 1978; 62: 961-4.
302. Sheshberadaran H, Shou-ni Chen, Norrby E. Monoclonal antibodies against five structural components of measles virus. *Virology.* 1983; 128: 341-53.
303. Silhar AS, Maru AM. Complications of measles. *Indian J. Child Health.* 1958; 7: 448-54.
304. Sinclair S. Vital statistics, India: Report on causes of death, Model Registration, 1969. *Indian Pediatr.* 1969; 11(1): 69-74.
305. Sinha NP. Measles in children under 6 months of age: An epidemiological study. *J. Trop. Pediatr.* 1981; 27(1): 120-2.
306. Smith T. Measles and the Government. *Br. Med. J.* 1987; 295: 989-90.
307. Stead S, Anderson CM. Measles elimination - identification of the unimmunised child. *Canadian J. Public Health.* 1984; 75(4): 266-9.
308. Steinhoff MC, John TJ. Appropriate strategy for immunisation of children in India. IV. Measles and its control, priority number one. *Indian J. Pediatr.* 1982; 49: 303-10.
309. Stetler HC, Orenstein WA, Bernier RH et al. Impact of revaccinating children who initially received measles vaccine before 10 months of age. *Pediatrics.* 1986; 77(4): 471-6.
310. Stokes J, Reilly CM, Hilleman MR, Buynak EB. Use of living attenuated measles virus vaccine in early infancy. *N. Engl. J. Med.* 1960; 263: 230-44.
311. Stokes J, Reilly CM, Buynak EB, Hilleman MR. Immunologic studies on measles. *Am. J. Hyg.* 1961; 74: 293-303.
312. Strauss, Zeimen. Epidemiological, microbiological and immunological characters of measles. *J. Hyg.* 1968; 9: 287-99.

313. Su W, Ze W, Zhang Y, Shao B, Liu Q. Study on the durability of immunity following revaccination with attenuated measles vaccine (in Chinese). *Liuxingbingxue Zezhi*. 1981; 2(1): 52-4. As cited in 361.
314. Suchman. Sociology and public health. *Trop. Geog. Med.* 1979; 31: 139-40.
315. Suguiro A. Field trial of trivalent MMR vaccine. *J. Infect. Dis.* 1982; 146(5): 709.
316. Sunderavalli N, Gowri M, Hussain MTA, Prema A. Post measles complications in infants and children. *Indian Pediatr.* 1979; 16(5): 437-9.
317. Taneja PN, Ghai OP, Bhakoo ON. Importance of measles to India. *Am. J. Dis. Child.* 1962; 103(3): 226-9.
318. Tarimo E. National plan of immunisation: In Kimati VP. The ten top childhood diseases and child health priorities in Tanzania. Dar-es-sallam. Univ. Dept. of Child Health. 1975; 208.
319. Terry LL. Opening Remarks. *Am. J. Dis. Child.* 1962; 103(3): 217.
320. Tianjin, Haerbin, Hangzhou, Tangshan, Guangxi. Antiepidemic stations (in Chinese) In: Forum on Measles vaccine. Changcheng. 1974; 300-310. As cited in 361.
321. Torigoe S, Biritwum RB, Isomura S et al. Measles in Ghana: A trial of an alternative means of administration of measles vaccine. *J. Trop. Pediatr.* 1986; 32(6): 304-9.
322. Udani PM, Shah PM. Analysis of the vital statistics from the rural community, Palghar. III: Preschool and school age mortalities. *Indian Pediatr.* 1969; 6: 759-69.
323. Ueda S, Okino Y, Sang Kavibha N et al. Studies of measles in Thailand. *Biken J.* 1967; 10: 129-33.
324. UNICEF: The State of the World's Children. 1984.
325. UNICEF: The State of the World's Children. 1985.

326. UNICEF: The State of the World's Children. 1986.
327. UNICEF: The State of the World's Children. 1987.
328. UNICEF: The State of the World's Children. 1988.
329. UNICEF: The State of the World's Children. 1989.
330. UNICEF: The State of the World's Children. 1990.
331. Vaccine withdrawn. Annotation. Lancet. 1969; 1: 1198.
332. Vaccination against measles. Editorial. Lancet. 1964; 2: 351.
333. Vaccination against measles: Clinical trial of live measles vaccine given alone and live vaccine preceded by killed vaccine. Third Report to the Medical Research Council by Measles Vaccine Committee. Practitioner. 1971; 206: 458-66.
334. Vasani K. Cord blood and maternal blood measles antibody titre. A study of 54 paired samples - July 1986. Personal communication.
335. Voorhoeve AM, Muller AS, Schulpen TWJ et al. Agents affecting health of mother and child in a rural area of Kenya. III. The epidemiology of measles. Trop. Geogr. Med. 1977; 29: 428-40.
336. Wallace RB, Landrigan PJ, Smith EA et al. Trial of a reduced dose of measles vaccine in Nigerian children. Bull. WHO. 1976; 53: 361-4.
337. Weibel RE, Buynak EB, McLean AA, Hilleman MR. Persistence of antibody after administration of monovalent and combined live attenuated measles, mumps and rubella virus vaccines. Pediatrics. 1978; 61: 5-11.
338. Weigle KA, Murphy MD, Brunell PA. Enzyme-linked immunosorbent assay for evaluation of immunity to measles virus. J. Clin. Microbiol. 1984; 19(3): 376-9.
339. Wesley A, Coovadia HM, Watson AR. Immunisation against measles in children at risk for severe disease. Trans. R. Soc. Trop. Med. Hyg. 1979; 73(6): 710-15.
340. White FMM. Policy for measles elimination in Canada and program implications. Rev. Infect. Dis. 1983; 5(3): 577-82.

341. Whittle HC, Rowland MGM, Mann GF, Lamb WH, Lewis RA. Immunisation of 4-6 months old Gambian infants with Edmonston-Zagreb measles vaccine. *Lancet*. 1984; 2: 834-7.
342. Whittle HC, Eccles M, Jupp L et al. Effects of dose and strain of vaccine on success of measles vaccination of infants aged 4-5 months. *Lancet*. 1988; 1: 963-6.
343. Wilkins J, Wehrle PF. Additional evidence against measles vaccine administration to infants less than 12 months of age: Altered immune response following active/passive immunisation. *J. Pediatr*. 1979; 94(6): 865-9.
344. Williams PJ, Hull HF. Status of measles in Gambia. *Rev. Infect. Dis*. 1983; 5(3): 391-4.
345. Willis T. The London practice of physics. London. 1965. As cited in 231.
346. Wilson GS. Session I. World-wide importance of measles: Measles as a universal disease. *Am. J. Dis. Child*. 1962; 103(3): 219-23.
347. Wood PB, Soheranda KS, Branken PM, Houser NE. Measles vaccination in Zaire - when and how? *Trans. R. Soc. Trop. Med. Hyg*. 1980; 74: 381-2.
348. World Health Organisation. Measles vaccines. Report of a World Health Organisation Scientific Group. *Tech. Rep. Ser.* 263. 1963; 1-37.
349. World Health Organisation Collaboration study: Measles immunity in the first year after birth and the optimum age for vaccination in Kenyan children. *Bull. WHO*. 1977; 55(1): 21-30.
350. World Health Organisation. Viral vaccines and antiviral drugs. Report of a WHO Scientific Group. *WHO Tech. Rep. Ser.* 693. 1983; 40-2.
351. World Health Organisation. Vaccines used in the EPI: indications and contraindications. *WHO Chronicle*. 1984; 38(3): 95-8.
352. Wu S, Xue X, Li E et al. Investigations on the cause of measles vaccination failure at early infancy (in Chinese). *Zhonghua Yixue Zazhi*. 1981; 61(2): 102-5. As cited in 361.

353. Wu S, Xue X, Zhang VH et al. An investigation of the causes of failures of measles vaccination in early infancy. *J. Biol. Stand.* 1982; 10: 197-203.
354. Xu T, Shao B, Xin J. Preliminary studies of reimmunisation with attenuated live measles vaccine (in Chinese). *Acta Microbiologica Sinica.* 1973; 13(2): 191-3. As cited in 361.
355. Yasyleya NA, Kashuba VN. Economic effectiveness of using a live measles vaccine in an agricultural area of the Ukrainian SSR. *Zh. Mikrobiol. Epidemiol. Immunobiol.* 1982; 9:57-60.
356. Yeager AS, Davis JH, Ross LA, Harvey BS. Measles immunisation - successes and failures. *JAMA.* 1977; 237: 347-51.
357. 'YOGARATNAKAR' - An Ayurvedic text. As cited in 72.
358. Yorke JA, Nathanson N, Pianigiani G, Martin J. Seasonality and the requirements for perpetuation and eradication of viruses in populations. *Am. J. Epidemiol.* 1979; 109: 103-23.
359. Zhang Y, Zhang Y. Problems of measles revaccination with Beijing 55 vaccine (in Chinese). In : Collections from the measles forum, Beijing. 1972; 26-9. As cited in 361.
360. Zhang Y, Su W. A review of current impact of measles in the People's Republic of China. *Rev. Infect. Dis.* 1983; 5(3): 411-6.
361. Zhang Y, Su W. Introduction to the control of measles by vaccination in the People's Republic of China. *Rev. Infect. Dis.* 1983; 5(3): 568-73.
362. Zhuji Collaborating Unit for the observation of duration of immunity of measles live vaccine. III. Observations on the results of revaccination of measles live vaccine. (in Chinese). *Zhonghua Yixue Zazhi.* 1980; 60(1): 9-13. As cited in 361.